Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2023

Newsfile March 17, 2023

Y-mAbs Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 20, 2023 to Discuss Your Rights - YMAB

Newsfile March 17, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Newsfile March 17, 2023

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Business Wire March 17, 2023

Bronstein, Gewirtz & Grossman, LLC Reminds Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and Last Day to Actively Participate

Newsfile March 17, 2023

3 DAYS UNTIL DEADLINE: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB) Lead Plaintiff Deadline is March 20, 2023

Newsfile March 17, 2023

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm's Attorneys Before Mar. 20th Deadline in Securities Fraud Class Action

Newsfile March 17, 2023

DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 17, 2023

YMAB SHAREHOLDER ALERT: Jakubowitz Law Reminds Y-mAbs Shareholders of a Lead Plaintiff Deadline of March 20, 2023

PR Newswire March 17, 2023

Y-mAbs Shareholder Action Reminder

Newsfile March 16, 2023

ROSEN, A LONGSTANDING LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMAB

Newsfile March 16, 2023

Y-MABS THERAPEUTICS, INC. (YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Newsfile March 16, 2023

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 20, 2023 in Y-mAbs Lawsuit - YMAB

Newsfile March 16, 2023

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 16, 2023

YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire March 16, 2023

Y-mAbs Shareholder Action Reminder

Newsfile March 15, 2023

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 15, 2023

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMAB

PR Newswire March 15, 2023

Y-mAbs Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 20, 2023 to Discuss Your Rights - YMAB

Newsfile March 15, 2023

YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire March 15, 2023